This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
zacks-consensus-estimate: Archive
Loar Holdings Inc. (LOAR) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Loar Holdings Inc. (LOAR) delivered earnings and revenue surprises of +21.05% and +2.37%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
LOARPositive Net Change POWWNo Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
IceCure Medical Ltd. (ICCM) Q2 Earnings Surpass Estimates
by Zacks Equity Research
IceCure Medical (ICCM) delivered earnings and revenue surprises of +200.00% and -34.38%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
ICCMPositive Net Change CODXPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
New to Investing? This 1 Computer and Technology Stock Could Be the Perfect Starting Point
by Zacks Equity Research
The Zacks Focus List offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.
LRCXPositive Net Change
earnings-estimates growth-investing zacks-consensus-estimate zacks-rank
Euroseas Ltd. (ESEA) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Euroseas (ESEA) delivered earnings and revenue surprises of +8.53% and +0.62%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
ESEANegative Net Change ZIMNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates
by Zacks Equity Research
Ovid Therapeutics (OVID) delivered earnings and revenue surprises of +62.50% and +4,225.52%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
OVIDNegative Net Change OCSNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Lucid Diagnostics Inc. (LUCD) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Lucid Diagnostics (LUCD) delivered earnings and revenue surprises of -11.11% and +29.22%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
LUCDNo Net Change ELMDNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
LiqTech International, Inc. (LIQT) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
LiqTech International (LIQT) delivered earnings and revenue surprises of -4.76% and -0.86%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
LIQTPositive Net Change DCINegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
VerifyMe, Inc. (VRME) Reports Q2 Loss, Beats Revenue Estimates
by Zacks Equity Research
VerifyMe (VRME) delivered earnings and revenue surprises of +66.67% and +5.61%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
VRMENegative Net Change YMMNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
XOMA Royalty (XOMA) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
XOMA Royalty (XOMA) delivered earnings and revenue surprises of +500.00% and +39.30%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
XOMAPositive Net Change HOWLNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
OrganiGram (OGI) Reports Q3 Loss, Beats Revenue Estimates
by Zacks Equity Research
OrganiGram (OGI) delivered earnings and revenue surprises of -200.00% and +5.86%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
OGINegative Net Change MGNXNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Madison Square Garden Entertainment (MSGE) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
MSG Entertainment (MSGE) delivered earnings and revenue surprises of -6.38% and -0.27%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
MSGENegative Net Change OXMNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Creative Realities, Inc. (CREX) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Creative Realities, Inc. (CREX) delivered earnings and revenue surprises of +133.33% and +7.42%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
CREXNegative Net Change ESTCPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Nayax (NYAX) Surpasses Q2 Earnings Estimates
by Zacks Equity Research
Nayax (NYAX) delivered earnings and revenue surprises of +60.00% and -2.26%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
NYAXPositive Net Change PAGSNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Gauzy Ltd. (GAUZ) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Gauzy Ltd. (GAUZ) delivered earnings and revenue surprises of -65.00% and -30.75%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
GAUZPositive Net Change DAKTNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Alithya Group (ALYAF) Beats Q1 Earnings Estimates
by Zacks Equity Research
Alithya (ALYAF) delivered earnings and revenue surprises of +25.00% and -0.76%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
ALYAFNegative Net Change SOPAPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Sapiens (SPNS) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Sapiens (SPNS) delivered earnings and revenue surprises of +6.25% and +1.07%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
SPNSPositive Net Change CRMNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Local Bounti Corporation (LOCL) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Local Bounti (LOCL) delivered earnings and revenue surprises of +16.41% and -1.60%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
LOCLPositive Net Change AVONegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Sanara MedTech Inc. (SMTI) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sanara MedTech (SMTI) delivered earnings and revenue surprises of +30.30% and +1.70%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
SMTINegative Net Change ANegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Arcos Dorados (ARCO) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Arcos Dorados (ARCO) delivered earnings and revenue surprises of +120.00% and +1.67%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
ARCONegative Net Change PDDNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Kamada (KMDA) Q2 Earnings Top Estimates
by Zacks Equity Research
Kamada (KMDA) delivered earnings and revenue surprises of +44.44% and -0.67%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
KMDANegative Net Change CVACPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Marex Group PLC (MRX) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Marex Group PLC (MRX) delivered earnings and revenue surprises of +10.87% and +7.18%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
MRXPositive Net Change XPNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Mersana Therapeutics (MRSN) delivered earnings and revenue surprises of -8.80% and -58.90%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
MRSNPositive Net Change RNANegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Performance Food Group (PFGC) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Performance Food (PFGC) delivered earnings and revenue surprises of +6.90% and +0.23%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
PFGCNegative Net Change SPTNNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Beats Revenue Estimates
by Zacks Equity Research
ARS Pharmaceuticals, Inc. (SPRY) delivered earnings and revenue surprises of -12.20% and +3.98%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
SPRYNegative Net Change NTRBNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Immatics (IMTX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Immatics (IMTX) delivered earnings and revenue surprises of -73.68% and -62.32%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
IMTXNegative Net Change DARENegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank